Compare SRL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | ADVM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 94.6M |
| IPO Year | N/A | 2014 |
| Metric | SRL | ADVM |
|---|---|---|
| Price | $6.32 | $4.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 9.9K | ★ 497.5K |
| Earning Date | 12-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 16.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,535,042.00 | N/A |
| Revenue This Year | N/A | $1,192.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $1.78 |
| 52 Week High | $9.99 | $6.12 |
| Indicator | SRL | ADVM |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 58.20 |
| Support Level | $5.85 | $4.15 |
| Resistance Level | $6.36 | $4.23 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 47.78 | 95.22 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.